EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix) 16.04.2023 / 21:01 CET/CESTThe issuer is solely responsible for the content of this.
According to 5-year follow-up data, the combination of tafasitamab-cxix and lenalidomide produced a durable response in patients with diffuse large B-cell lymphoma.
EQS-News: MorphoSys AG / Key word: Miscellaneous
MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL. | April 16, 2023
Results from the Phase 2 L-MIND study were highlighted as a late-breaking oral presentation at the American Association for Cancer Research Annual Meeting 2023 MorphoSys U.S. Inc., a fully owned subsidiary
16.04.2023 - EQS-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi (tafasitamab-cxix) 16.04.2023 / .